LumaVida Women’s Health Institute Business Plan — The Network & Clinic Economics

LumaVida’s economics are those of a capital-light specialist-outpatient rollout: build a flagship clinic, prove the model, and replicate it across the provinces, funding much of the expansion from the operating cash the earlier clinics generate. This section sets out the clinic format and unit economics, the rollout plan and its funding, the staffing model and its binding specialist constraint, and the operating assumptions used throughout the financial model. Consistent with the Important Notice, clinic revenue and margin figures are planning assumptions built to be consistent with the sponsor’s illustrative figures and benchmarked to South African women’s-health economics.

The clinic format and unit economics

A flagship LumaVida clinic is 800–1,200 square metres in a premium medical precinct, with eight consultation rooms, ultrasound rooms, a minor-procedure room, a laboratory collection point, a pharmacy partnership and a wellness lounge. It costs roughly R13–15 million to build and equip, a fraction of a hospital’s cost, because surgery and deliveries are performed in partner hospitals. Critically, a clinic is profitable in its first year: the sponsor’s illustrative flagship generates about R16.5 million of revenue and R4.5 million of clinic EBITDA in Year 1, maturing toward a ~R21 million run-rate.

Metric	Mature clinic	Basis
Clinic size	800–1,200 sqm	Premium medical precinct
Build & equip cost	~R13–15m	Fit-out R8m + equipment R5m
Consultation rooms	8	Plus ultrasound & minor-procedure rooms
Mature revenue	~R21m/year	Blended across five service lines
Clinic EBITDA margin	~27–30%	Before head-office allocation
Staff per clinic	~24	4 OB/GYNs, 2 sonographers, nurses, admin
Year-1 profitability	Positive	Profitable in its first year

StrengthA capital-light, profitable-from-Year-1 model

The defining financial feature of LumaVida is that it is not a heavy-capital healthcare business. By partnering with hospitals for surgery rather than owning theatres, each clinic is inexpensive to build and profitable in its first year, so there is no deep, multi-year J-curve trough. This capital efficiency drives strong returns on capital and lets the network fund much of its own rollout from operating cash flow. It is the single most attractive structural feature of the plan, and the reason a relatively modest external raise can build a national platform.

The rollout ramp

LumaVida rolls out from one clinic to nine over five years: the Johannesburg flagship in Year 1, a metro-led expansion (Pretoria, Cape Town, Durban) through Years 2–3, and the remaining provinces by Year 5. Each clinic ramps quickly, to about 82% of mature revenue in its first year and full maturity by year three, because outpatient demand builds faster than a surgical centre’s. Network revenue therefore climbs from about R17 million to R180 million as clinics open and mature.

Figure 7. *Clinic rollout and network maturity*

Figure 8. *Nine provincial clinics — phased rollout*

Funding the rollout — the R25m seed is Phase 1 only

This is the most important point for prospective investors to understand. The R25 million initial funding is the Phase-1 seed, it funds the Johannesburg flagship, the digital platform, recruitment, launch marketing and initial working capital. It does not fund the national network. Building all nine clinics requires roughly R132 million of capital over five years; even a capital-light model cannot self-fund that entirely from operating cash. The plan therefore requires a Phase-2 follow-on raise: our model assumes about R120 million of external funding in total (approximately R85 million of equity, including the R25 million seed, and R35 million of development finance), with the remainder funded by reinvested operating cash flow.

Figure 9. *The R25m seed is Phase 1 — not the full programme*

Analyst flagThe headline R25m understates the national programme roughly five-fold

A prospective seed investor should be clear-eyed: R25 million launches the flagship and the platform, but the national vision, nine clinics, R180 million of revenue, requires around R132 million of capital. The capital-light model does much of the heavy lifting (roughly a third of the programme is funded from reinvested operating cash), but the plan still depends on a substantial Phase-2 follow-on raise once the flagship has proven the model. Investors backing the full vision must underwrite that Phase-2 funding path from the outset; investors backing only the seed should understand they are funding proof-of-concept, not the national chain.

The staffing model and the specialist constraint

Each clinic is staffed by roughly 24 people, four obstetrician-gynaecologists, two sonographers, three nurses, a fertility-specialist partner, a dietitian, a psychologist and an administration team, with a national head office and platform team. Across nine clinics the network employs over 200 people. But the number that matters is 36, the OB/GYNs, because women’s-health specialists, and fertility subspecialists in particular, are the scarce, binding input.

Figure 10. *Employment at scale — around 225 nationwide*

Analyst flagRecruiting OB/GYNs — and fertility subspecialists — is the central risk

South Africa’s obstetrician-gynaecologists are concentrated in the metros, and reproductive-medicine subspecialists are acutely scarce, subspecialty training is offered at only two to three centres nationally, waiting lists for training run to years, and only 10–13% of the country’s fertility need is met. Staffing four OB/GYNs per clinic across nine provinces, including under-served provinces where women’s-health specialists are thin, means competing for a scarce national resource. The fertility ambition is the most constrained of all, which is why LumaVida pursues it through laboratory and subspecialist partnerships rather than trying to own scarce embryology capacity. Mitigation, competitive packages and equity participation, partnership models, task-sharing with nurses and sonographers, tele-consultation and the digital platform, is central to the plan, and the metro clinics will staff and ramp more reliably than the rural ones.

How the network revenue builds

The network revenue is the sum of clinic cohorts at different stages of maturity in any given year. The table shows how revenue builds as each cohort ramps, the flagship (opened Year 1) maturing first, and the later cohorts still ramping toward the ~R21m mature run-rate at the end of the plan.

	Year 1	Year 2	Year 3	Year 4	Year 5
Clinics open	1	3	5	7	9
Network maturity	9%	29%	51%	73%	95%
Revenue (R m)	17	55	96	138	180
Revenue per open clinic (R m)	17	18	19	20	20

Figure 11. *Average revenue per open clinic — rising as clinics mature*

Working capital and medical-aid receivables

Working capital is dominated by medical-aid receivables: a substantial share of consultation, diagnostic and procedure revenue is reimbursed by medical schemes on 30–60 day terms. The model sets net working capital at about 9% of revenue. The membership subscription is a helpful counterweight, it is collected in advance monthly, improving cash conversion, but efficient medical-aid claims administration and collections remain operationally critical, and a central revenue-cycle function is built into the head-office model.